This Article Full Text (PDF) All Versions of this Article: 0269881108089816v1 23/2/157    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Afshar, H Articles by Talaei, M Search for Related Content PubMed PubMed Citation Articles by Afshar, H Articles by Talaei, M Social Bookmarking                         What's this?

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

H Roohafza

Mental Health Department, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran roohafza{at}crc.mui.ac.ir

G Mousavi

Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

S Golchin

Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

N Toghianifar

Mental Health Department, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

M Sadeghi

Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences. Isfahan, Iran

M Talaei

COX Research Group, Consultation Department, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Glutamate antagonists such as topiramate have been proposed based on the glutamate hypothesis of schizophrenia because its properties encourage its exploration and possible development as a medication for the treatment of schizophrenia. A randomised, double-blind, placebo-controlled clinical trial was performed on 18- to 45-year-old patients with schizophrenia. Baseline information including vital signs, height, weight, smoking status, demographic characteristics, (past) psychiatric history, medication history and medication-related adverse effects were collected. Patients were randomly assigned to a topiramate or placebo group. Efficacy of medication was measured by administering Positive and Negative Syndrome Scale (PANSS), and tolerability of treatment was recorded on day 0 (baseline), day 28 and day 56. PANSS values (95% confidence interval) at baseline, day 28 and day 56 in the topiramate group were 96.87 (85.37–108.37), 85.68 (74.67–96.70) and 76.87 (66.06–87.69), respectively; compared with 101.87 (90.37–113.37), 100.31 (89.29–111.32) and 100.56 (89.74–111.37) in the placebo group. General linear model for repeated measures analysis showed that topiramate has lowered PANSS values significantly compared with the placebo group. Similar significant decline patterns were found in all three subscales (negative, positive and psychopathology sign). Clinical response (more than 20% reduction in PANSS) was significantly higher in topiramate-treated subjects than controls (50% vs 12.5%). Topiramate can be an effective medication in controlling schizophrenic symptoms, considering its effect on negative symptoms and controlling antipsychotic-associated weight gain.

Key Words: clinical trial • PANSS • schizophrenia • topiramate

This version was published on March 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 2, 157-162 (2009)
DOI: 10.1177/0269881108089816


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?